Zacks Small Cap Has Pessimistic View of ENSC Q1 Earnings

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Zacks Small Cap reduced their Q1 2025 earnings per share estimates for Ensysce Biosciences in a research note issued on Tuesday, March 11th. Zacks Small Cap analyst B. Sorensen now expects that the company will post earnings per share of ($4.50) for the quarter, down from their prior forecast of ($3.84). The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($8.33) per share. Zacks Small Cap also issued estimates for Ensysce Biosciences’ Q2 2025 earnings at ($4.50) EPS, Q3 2025 earnings at ($3.00) EPS, Q4 2025 earnings at ($1.81) EPS, FY2025 earnings at ($14.81) EPS and FY2026 earnings at $42.42 EPS.

Ensysce Biosciences (NASDAQ:ENSC) last posted its earnings results on Monday, March 10th. The company reported ($2.90) EPS for the quarter, missing the consensus estimate of ($2.74) by ($0.16). Ensysce Biosciences had a negative return on equity of 292.81% and a negative net margin of 179.26%. The company had revenue of $1.30 million during the quarter, compared to analysts’ expectations of $0.25 million.

Ensysce Biosciences Price Performance

ENSC stock opened at $3.89 on Thursday. The firm has a 50-day moving average of $6.27 and a 200 day moving average of $6.48. The company has a market cap of $5.08 million, a P/E ratio of -0.14 and a beta of 0.64. Ensysce Biosciences has a 1 year low of $2.12 and a 1 year high of $14.67.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Ensysce Biosciences stock. Anson Funds Management LP purchased a new position in Ensysce Biosciences, Inc. (NASDAQ:ENSC) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 983,518 shares of the company’s stock, valued at approximately $236,000. Anson Funds Management LP owned 11.15% of Ensysce Biosciences as of its most recent SEC filing. Hedge funds and other institutional investors own 5.63% of the company’s stock.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.